Recently, we demonstrated in yeast that MSH2 affects BRCA1-induced HR and, in parallel, we found a high frequency (36%) of MSH2 somatic mutations in breast and ovarian tumors from BRCA1 missense variant carriers (Maresca et al., 2015). This evidence concerns the gene MSH2 and ovarian neoplasm.